|
JP2961045B2
(ja)
|
1993-02-24 |
1999-10-12 |
日清製粉株式会社 |
腸管粘膜増強促進剤
|
|
US6184208B1
(en)
|
1994-06-29 |
2001-02-06 |
Immunotech Developments Inc. |
Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
|
|
US6184201B1
(en)
|
1995-04-14 |
2001-02-06 |
Nps Allelix Corp. |
Intestinotrophic glucagon-like peptide-2 analogs
|
|
US5834428A
(en)
|
1995-04-14 |
1998-11-10 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
US5789379A
(en)
|
1995-04-14 |
1998-08-04 |
Allelix Biopharmaceutical Inc. |
Glucagon-like peptide-2 analogs
|
|
US5912229A
(en)
|
1996-03-01 |
1999-06-15 |
Novo Nordisk Als |
Use of a pharmaceutical composition comprising an appetite-suppressing peptide
|
|
DE69740176D1
(de)
|
1996-03-01 |
2011-05-26 |
Novo Nordisk As |
Appetithemmendes Peptid, Zusammensetzung und Verwendung
|
|
EP1231219B1
(en)
|
1996-04-12 |
2010-08-25 |
1149336 Ontario Inc. |
GLucagon-like peptide-2 analogs
|
|
US5994500A
(en)
|
1996-07-19 |
1999-11-30 |
1149336 Ontario Inc. |
Antagonists of intestinotrophic GLP-2 peptides
|
|
US20020025933A1
(en)
|
1996-08-30 |
2002-02-28 |
Knudsen Liselotte Bjerre |
GLP-2 derivatives
|
|
AU723268B2
(en)
|
1996-09-09 |
2000-08-24 |
Zealand Pharma A/S |
Improved solid-phase peptide synthesis and agent for use in such synthesis
|
|
US5952301A
(en)
|
1996-12-10 |
1999-09-14 |
1149336 Ontario Inc. |
Compositions and methods for enhancing intestinal function
|
|
CA2236519C
(en)
|
1997-05-02 |
2011-09-13 |
1149336 Ontario Inc. |
Methods of enhancing functioning of the large intestine
|
|
CA2289652C
(en)
|
1997-05-16 |
2012-02-28 |
1149336 Ontario Inc. |
Methods of enhancing functioning of the upper gastrointestinal tract
|
|
US6051557A
(en)
|
1997-05-16 |
2000-04-18 |
1149336 Ontario Inc. |
Methods of enhancing functioning of the upper gastrointestinal tract
|
|
EP2583675A1
(en)
|
1998-02-02 |
2013-04-24 |
Trustees Of Tufts College |
Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
|
|
NZ506839A
(en)
|
1998-03-09 |
2003-05-30 |
Zealand Pharma As |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
AU7421598A
(en)
|
1998-05-11 |
1999-11-29 |
1149336 Ontario Inc. |
Methods of enhancing functioning of the large intestine
|
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
|
AU2020501A
(en)
|
1999-12-08 |
2001-06-18 |
1149336 Ontario Inc. |
Chemotherapy treatment
|
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
|
EP1970072A1
(en)
|
2000-09-18 |
2008-09-17 |
Sanos Bioscience A/S |
Use of GLP-2 peptides for the treatment of hyperparathyroidism
|
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
|
US7186683B2
(en)
|
2000-09-18 |
2007-03-06 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
|
WO2002066062A2
(en)
|
2001-02-01 |
2002-08-29 |
Drucker Daniel J |
Enhancement of glp-2 activity
|
|
DK1360202T3
(da)
|
2001-02-16 |
2008-09-22 |
Conjuchem Biotechnologies Inc |
Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
|
|
AU2002308706A1
(en)
|
2001-06-01 |
2002-12-16 |
Eli Lilly And Company |
Glp-1 formulations with protracted time action
|
|
WO2004035624A2
(en)
|
2002-10-14 |
2004-04-29 |
Novo Nordisk A/S |
Glucagon - like peptide - 2 variants
|
|
RU2329823C2
(ru)
|
2002-10-29 |
2008-07-27 |
Алза Корпорейшн |
Стабилизированные твердые полипептидные частицы
|
|
BR122019021416A2
(https=)
|
2003-09-19 |
2019-12-21 |
|
|
|
DK3300721T4
(da)
|
2003-11-20 |
2025-03-03 |
Novo Nordisk As |
Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
|
|
US20050256036A1
(en)
|
2004-01-27 |
2005-11-17 |
Boyle Bryan J |
Gastrointestinal proliferative factor and uses thereof
|
|
WO2005082404A2
(en)
|
2004-02-27 |
2005-09-09 |
Novo Nordisk A/S |
Glp-2 derivatives modified by lipophilic substituents
|
|
EP1809318B1
(en)
*
|
2004-11-01 |
2013-06-12 |
NPS Pharmaceuticals, Inc. |
Treatment of short bowel syndrome patients with colon-in-continuity
|
|
WO2007022123A2
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
UA95235C2
(en)
|
2005-05-04 |
2011-07-25 |
Зииланд Фарма А/С |
Glucagon-like-peptide-2 (glp-2) analogues
|
|
CN101331224A
(zh)
*
|
2005-10-24 |
2008-12-24 |
森托科尔公司 |
Glp-2模拟体、多肽、组合物、方法和用途
|
|
CN101341254A
(zh)
|
2005-12-24 |
2009-01-07 |
蒂加斯克乳制品研究中心 |
反-10，顺-12十八碳二烯酸的生产方法
|
|
US20090028832A1
(en)
|
2006-08-10 |
2009-01-29 |
Chung Leland F |
Compositions and methods for targeted tumor therapy
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
CN101573376B
(zh)
|
2006-11-08 |
2013-11-06 |
西兰制药公司 |
选择性胰高血糖素样肽-2（glp-2）类似物
|
|
CN101668535B
(zh)
|
2006-12-29 |
2017-07-28 |
益普生制药股份有限公司 |
Glp‑1药物组合物
|
|
GB0700523D0
(en)
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
|
CA2677932A1
(en)
|
2007-02-15 |
2008-08-21 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
AR072160A1
(es)
|
2008-06-17 |
2010-08-11 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1
|
|
CN102282167B
(zh)
|
2008-12-15 |
2014-08-13 |
西兰制药公司 |
胰高血糖素类似物
|
|
PE20120332A1
(es)
|
2008-12-19 |
2012-04-14 |
Univ Indiana Res & Tech Corp |
Profarmacos de peptido de la superfamilia de glucagon basado en amida
|
|
CN101824087A
(zh)
|
2009-03-05 |
2010-09-08 |
连云港恒邦医药科技有限公司 |
胰高血糖素样肽-2类似物及其制备方法和用途
|
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
CN102933598A
(zh)
|
2010-03-26 |
2013-02-13 |
诺沃—诺迪斯克有限公司 |
新型胰高血糖素类似物
|
|
KR20130115086A
(ko)
|
2010-05-17 |
2013-10-21 |
세빅스 인코포레이티드 |
페길화된 c-펩티드
|
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
EP2588126A4
(en)
|
2010-06-24 |
2015-07-08 |
Univ Indiana Res & Tech Corp |
AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
|
|
CN102212127B
(zh)
|
2011-05-17 |
2015-02-04 |
上海景泽生物技术有限公司 |
胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途
|
|
DK2710031T3
(en)
|
2011-05-18 |
2018-01-02 |
Mederis Diabetes Llc |
IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE
|
|
JP6206972B2
(ja)
*
|
2011-09-12 |
2017-10-04 |
アムニクス オペレーティング インコーポレイテッド |
グルカゴン様ペプチド−２組成物およびその作製法および使用法
|
|
CN104540850B
(zh)
|
2012-05-03 |
2018-05-18 |
西兰制药公司 |
胰高血糖素样肽2(glp-2)类似物
|
|
IN2015DN00544A
(https=)
|
2012-07-23 |
2015-06-26 |
Zealand Pharma As |
|
|
US9018162B2
(en)
|
2013-02-06 |
2015-04-28 |
Xeris Pharmaceuticals, Inc. |
Methods for rapidly treating severe hypoglycemia
|
|
US20160067311A1
(en)
*
|
2014-09-10 |
2016-03-10 |
Helsinn Healthcare Sa |
Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
|
|
WO2016065181A1
(en)
|
2014-10-23 |
2016-04-28 |
Amgen Inc. |
Reducing viscosity of pharmaceutical formulations
|
|
CN107257681A
(zh)
|
2014-12-23 |
2017-10-17 |
卡姆拉斯公司 |
控释配制品
|
|
BR112017014994B1
(pt)
|
2015-02-17 |
2023-12-19 |
Eli Lilly And Company |
Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
|
|
WO2017053822A1
(en)
|
2015-09-23 |
2017-03-30 |
Behavioral Recognition Systems, Inc. |
Detected object tracker for a video analytics system
|
|
LT3541366T
(lt)
|
2016-11-21 |
2025-03-10 |
Amylyx Pharmaceuticals, Inc. |
Eksendino (9-39) buferiniai preparatai
|
|
EP3551651B1
(en)
|
2016-12-09 |
2024-03-06 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018142363A1
(en)
|
2017-02-06 |
2018-08-09 |
Orbicular Pharmaceutical Technologies Private Limited |
Ready to use compositions of glp-2 analogues through self-administrable devices
|
|
IL299864B2
(en)
|
2017-06-16 |
2024-06-01 |
Zealand Pharma As |
Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
|
|
GB201710822D0
(en)
|
2017-07-05 |
2017-08-16 |
Zealand Pharma As |
Methods and medical uses relating to the treatment of hypoglycaemia
|
|
US20190275110A1
(en)
|
2017-12-07 |
2019-09-12 |
Adocia |
Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid
|
|
WO2020020904A1
(en)
|
2018-07-23 |
2020-01-30 |
Zealand Pharma A/S |
Therapeutic uses of glp-2 agonists
|
|
EP3628683A1
(en)
|
2018-09-28 |
2020-04-01 |
Zealand Pharma A/S |
Formulations of glucagon-like-peptide-2 (glp-2) analogues
|
|
CA3129576A1
(en)
*
|
2019-02-11 |
2020-08-20 |
Opko Biologics Ltd. |
Long-acting glp-2 analogs
|